Novavax, Inc. · NASDAQ:NVAX

Novavax — Second ISV COVID-19 Vaccines Virtual Congress (July 2020)

16 slides from Novavax's conference presentation, Jul 21, 2020

  1. Slide 1: Second ISV COVID-19 Vaccines Virtual Congress

    Second ISV COVID-19 Vaccines Virtual Congress 21 July 2020

  2. Slide 2: Novavax in brief

    Novavax in brief We are a late-stage biotechnology company developing innovative vaccines to prevent serious infectious diseases based on two proprietary technologies: 1. Recombinant antigen manufacturing platform combines the power and speed of genetic engineering to efficiently produce a new class

  3. Slide 3: Advancing the next generation of revolutionary vaccines

    Advancing the next generation of revolutionary vaccines

  4. Slide 4: NVX-CoV2373: A full-length, prefusion stabilized SARS-CoV-2 spike glycoprotein

    NVX-CoV2373: A full-length, prefusion stabilized SARS-CoV-2 spike (S) glycoprotein • Full-length spike protein stabilized with two mutations • Trimers are formulated into a stable detergent/protein nanoparticle Spike Trimer Nanoparticle • Adjuvanted with Matrix M, two fractions of Quillaja saponaria

  5. Slide 5: NVX-CoV2373 binds with high affinity to hACE2 receptor

    NVX-CoV2373 binds with high affinity to hACE2 receptor Binding is an indication of the correct prefusion structure, predicts induction of functional antibodies that will block infection hACE2 binding NVX-CoV2373 Octet (BLI) hACE2 binding NVX-CoV2373 (ELISA) Tian et al., bioRxiv, July 2020 5

  6. Slide 6: NVX-CoV2373 appears stable under various environmental conditions

    NVX-CoV2373 appears stable under various environmental conditions Tian et al., bioRxiv, July 2020 6

  7. Slide 7: NVX-CoV2373 vaccine NHP immunogenicity and protection SARS-CoV-2

    NVX-CoV2373 vaccine NHP immunogenicity and protection SARS-CoV-2

  8. Slide 8: Baboons: NVX-CoV2373 Anti-S IgG ELISA and neutralizing antibody responses

    Baboons: NVX-CoV2373 vaccine Anti-S IgG ELISA and neutralizing antibody responses **Matt Frieman, UMD School of Medicine BSL3 SARS-CoV-2 virus infection Vero E6 cell 100% CPE Tian et al., bioRxiv, July 2020 8

  9. Slide 9: Cynomolgus macaques: NVX-CoV2373 induced anti-S and neutralizing antibodies

    Cynomolgus macaques: NVX-CoV2373 vaccine induced anti-S and neutralizing antibodies 9

  10. Slide 10: Cynomolgus macaques: BAL protection SARS-CoV-2 RNA and sgRNA

    Cynomolgus macaques: NVX-CoV2373 vaccine BAL protection SARS-CoV-3 RNA and Subgenomic RNA (sgRNA) 10

  11. Slide 11: Cynomolgus macaques: nasal protection SARS-CoV-2 RNA and sgRNA

    Cynomolgus macaques: NVX-CoV2373 vaccine nasal protection SARS-CoV-3 RNA and Subgenomic RNA (sgRNA) 11

  12. Slide 12: Matrix-M adjuvant increases Spike antigen specific T cells

    Matrix-M adjuvant increases the absolute numbers of Spike antigen specific T cells and proportion of multifunctional T Cells Tian et al., bioRxiv, July 2020 12

  13. Slide 13: NVX-CoV2373 Clinical development overview

    NVX-CoV2373 Clinical development overview

  14. Slide 14: NVX-CoV2373 Phase 1 clinical trial

    NVX-CoV2373 Phase 1 clinical trial N=131, Adults 18-59 y/o in Australia N=131 Day 0 Day 21 Antigen Matrix-M Antigen Matrix-M A 25 Placebo Placebo B 25 25 µg 25 µg C 25 (+3) 5 µg + 50 µg 5 µg + 50 µg D 25 (+3) 25 µg + 50 µg 25 µg + 50 µg E 25 25 µg + 50 µg Placebo Development goal: • FTiH safety • Do

  15. Slide 15: Accelerating NVX-CoV2373 to address worldwide COVID pandemic

    Accelerating NVX-CoV2373 to address worldwide COVID pandemic • Novavax is a late-stage biotechnology company focused on viral respiratory diseases • NVX-CoV2373 is a full-length recombinant prefusion Spike protein nanoparticle adjuvanted with Matrix M • Preclinical studies demonstrates that the vacc

  16. Slide 16: eonity ale

    e , 7 © @) eonity ale ie 2 56 oe NOVAVA wee AX Creating ae,

Novavax — Second ISV COVID-19 Vaccines Virtual Congress (July 2020) on 6ix